DOCSLIB.ORG

About Breast Cancer in Men Overview and Types

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

cancer.org | 1.800.227.2345 About Breast Cancer in Men Overview and Types If you have been diagnosed with breast cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. ● What Is Breast Cancer in Men? Research and Statistics See the latest estimates for new cases of breast cancer in men and deaths in the US and what research is currently being done. ● Key Statistics for Breast Cancer in Men ● What's New in Research for Breast Cancer in Men? What Is Breast Cancer in Men? Breast cancer occurs mainly in women, but men can get it, too. Many people do not realize that men have breast tissue and that they can develop breast cancer. Cells in nearly any part of the body can become cancer and can spread to other areas. Breast cancer starts when cells in the breast begin to grow out of control. These cells usually form a tumor that can often be seen on an x-ray or felt as a lump. The tumor is malignant (cancer) if the cells can grow into (invade) surrounding tissues or spread 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 (metastasize) to distant areas of the body. To learn more about how cancers start and spread, see Cancer Basics1. Male breast tissue Until puberty (on average around age 9 or 10), young boys and girls have a small amount of breast tissue consisting of a few ducts located under the nipple and areola (area around the nipple). At puberty, a girl's ovaries make female hormones, causing breast ducts to grow and lobules to form at the ends of ducts. Even after puberty, boys and men normally have low levels of female hormones, and breast tissue doesn’t grow much. Men's breast tissue has ducts, but only a few if any lobules. Where breast cancer starts Breast cancers can start from different parts of the breast. Most breast cancers begin in the ducts that carry milk to the nipple (ductal cancers). Some start in the glands that make breast milk (lobular cancers). Men have these ducts and glands, too, even though they aren't normally functional. There are also types of breast cancer that start in other types of breast cells, but these are less common. A small number of cancers start in other tissues in the breast. These cancers are called sarcomas2 and lymphomas3 and are not really thought of as breast cancers. Although many types of breast cancer can cause a lump in the breast, not all do. There are other symptoms of breast cancer you should watch for4 and report to a health care provider. It’s also important to understand that most breast lumps are benign and not cancer (malignant). Benign breast tumors are abnormal growths, but they do not spread outside of the breast and they are not life threatening. Any breast lump or change needs to be checked by a health care provider to determine whether it is benign or malignant (cancer) and whether it might impact your future cancer risk. How breast cancer spreads Breast cancer can spread when the cancer cells get into the blood or lymph system and are carried to other parts of the body. The lymph system is a network of lymph (or lymphatic) vessels found throughout the body. The lymph vessels carry lymph fluid and connect lymph nodes. Lymph nodes 2 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 are small, bean-shaped collections of immune system cells. Lymph vessels are like small veins, except that they carry a clear fluid called lymph (instead of blood) away from the breast. Lymph contains tissue fluid and waste products, as well as immune system cells. Breast cancer cells can enter lymph vessels and start to grow in lymph nodes. Most of the lymph vessels of the breast drain into: ● Lymph nodes under the arm (axillary nodes) ● Lymph nodes around the collar bone (supraclavicular [above the collar bone] and infraclavicular [below the collar bone] lymph nodes) ● Lymph nodes inside the chest near the breast bone (internal mammary lymph nodes) If the cancer cells have spread to your lymph nodes, there is a higher chance that the cells could have also traveled through the lymph system and spread (metastasized) to other parts of your body. The more lymph nodes with breast cancer cells, the more likely it is that the cancer may be found in other organs. Because of this, finding cancer in one or more lymph nodes often affects your treatment plan. Usually, surgery to remove one or more lymph nodes5 will be needed to know whether the cancer has spread. Still, not all men with cancer cells in their lymph nodes develop metastases to other areas, and some men can have no cancer cells in their lymph nodes and later develop metastases. Benign breast conditions Men can also have some benign (not cancerous) breast disorders. Gynecomastia Gynecomastia is the most common male breast disorder. It is not a tumor but rather an increase in the amount of a man's breast tissue. Usually, men have too little breast tissue to be felt or noticed. Gynecomastia can appear as a button-like or disk-like growth under the nipple and areola (the dark circle around the nipple), which can be felt and sometimes seen. Some men have more severe gynecomastia and they may appear to have small breasts. Although gynecomastia is much more common than breast cancer in men, both can be felt as a growth under the nipple, which is why it's important to have any such lumps checked by your doctor. Gynecomastia is common among teenage boys because the balance of hormones in 3 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 the body changes during adolescence. It is also common in older men due to changes in their hormone balance. In rare cases, gynecomastia occurs because tumors or diseases of certain endocrine (hormone-producing) glands cause a man's body to make more estrogen (the main female hormone). Men's glands normally make some estrogen, but not enough to cause breast growth. Diseases of the liver, which is an important organ in male and female hormone metabolism, can change a man's hormone balance and lead to gynecomastia. Obesity (being extremely overweight) can also cause higher levels of estrogen in men. Some medicines can cause gynecomastia. These include some drugs used to treat ulcers and heartburn, high blood pressure, heart failure, and psychiatric conditions. Men with gynecomastia should ask their doctors if any medicines they are taking might be causing this condition. Klinefelter syndrome, a rare genetic condition, can lead to gynecomastia as well as increase a man's risk of developing breast cancer. This condition is discussed further in Risk Factors for Breast Cancer in Men6. Benign breast tumors There are many types of benign breast tumors (abnormal lumps or masses of tissue), such as papillomas and fibroadenomas. Benign tumors do not spread outside the breast and are not life threatening. Benign breast tumors are common in women but are very rare in men. Types of Breast Cancer in Men The most common types of breast cancer are ductal carcinoma in situ, invasive ductal carcinoma, and invasive lobular carcinoma. Most breast cancers are carcinomas. In fact, breast cancers are often a type of carcinoma called adenocarcinoma, which starts in cells that make glands (glandular tissue). Breast adenocarcinomas start in the ducts (the milk ducts) or the lobules (milk- producing glands). There are other, less common, types of breast cancers, too, such as sarcomas, phyllodes, Paget’s disease and angiosarcomas which start in the cells of the muscle, fat, or connective tissue. Sometimes a single breast tumor can be a combination of different types. And in some 4 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 very rare types of breast cancer, the cancer cells may not form a lump or tumor at all. When a biopsy is done to find out the specific type of breast cancer, the pathologist also will say if the cancer has spread in to the surrounding tissues. The name of the breast cancer type will change depending on the extent of the cancer. ● In situ breast cancers have not spread. ● Invasive or infiltrating cancers have spread (invaded) into the surrounding breast tissue. These general kinds of breast cancer can be further described with the terms outlined above. Ductal carcinoma in situ Ductal carcinoma in situ (DCIS; also known as intraductal carcinoma) is considered non-invasive or pre-invasive breast cancer. In DCIS (also known as intraductal carcinoma), cells that lined the ducts have changed to look like cancer cells. The difference between DCIS and invasive cancer is that the cells have not spread (invaded) through the walls of the ducts into the surrounding tissue of the breast (or spread outside the breast). DCIS is considered a pre-cancer because some cases can go on to become invasive cancers. Right now, though, there is no good way to know for certain which cases will go on to become invasive cancers and which ones won’t. DCIS accounts for about 1 in 10 cases of breast cancer in men. It is almost always curable with surgery.7 Lobular carcinoma in situ Lobular carcinoma in situ (LCIS)8 may also be called lobular neoplasia. In LCIS, cells that look like cancer cells are growing in the lobules of the milk-producing glands of the breast, but they haven’t grown through the wall of the lobules.
Recommended publications
  • DCIS): Pathological Features, Differential Diagnosis, Prognostic Factors and Specimen Evaluation

    DCIS): Pathological Features, Differential Diagnosis, Prognostic Factors and Specimen Evaluation

    Modern Pathology (2010) 23, S8–S13 S8 & 2010 USCAP, Inc. All rights reserved 0893-3952/10 $32.00 Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation Sarah E Pinder Breast Research Pathology, Research Oncology, Division of Cancer Studies, King’s College London, Guy’s Hospital, London, UK Ductal carcinoma in situ (DCIS) is a heterogeneous, unicentric precursor of invasive breast cancer, which is frequently identified through mammographic breast screening programs. The lesion can cause particular difficulties for specimen handling in the laboratory and typically requires even more diligent macroscopic assessment and sampling than invasive disease. Pitfalls and tips for macroscopic handling, microscopic diagnosis and assessment, including determination of prognostic factors, such as cytonuclear grade, presence or absence of necrosis, size of the lesion and distance to margins are described. All should be routinely included in histopathology reports of this disease; in order not to omit these clinically relevant details, synoptic reports, such as that produced by the College of American Pathologists are recommended. No biomarkers have been convincingly shown, and validated, to predict the behavior of DCIS till date. Modern Pathology (2010) 23, S8–S13; doi:10.1038/modpathol.2010.40 Keywords: ductal carcinoma in situ (DCIS); breast cancer; histopathology; prognostic factors Ductal carcinoma in situ (DCIS) is a malignant, lesions, a good cosmetic result can be obtained by clonal proliferation of cells growing within the wide local excision. Recurrence of DCIS generally basement membrane-bound structures of the breast occurs at the site of previous excision and it is and with no evidence of invasion into surrounding therefore better regarded as residual disease, as stroma.
  • A Case of Male Breast Cancer with a BRCA Gene Mutation

    A Case of Male Breast Cancer with a BRCA Gene Mutation

    CASE REPORT The Ochsner Journal 15:448–451, 2015 Ó Academic Division of Ochsner Clinic Foundation A Case of Male Breast Cancer with a BRCA Gene Mutation Martin A. Benjamin, MD,1 Adam I. Riker, MD, FACS2 1Department of Surgery, University of Illinois at Chicago, Chicago, IL 2Advocate Cancer Institute, Advocate Christ Medical Center, Oak Lawn, IL Background: Male breast cancer (MBC) is an uncommon malignancy with an incidence that accounts for about 1% of all breast cancer cases. It commonly presents as a locally advanced tumor that has already spread to the regional nodal basin. Similar to female breast cancers, MBC gene expression profiling and tumor studies help to detect molecular subtypes of tumors that correlate with clinical outcome and mortality rates. Case Report: We report a relatively uncommon case of a 64-year-old male with a BRCA1þ gene mutation that is also found to be HER2þ on receptor analysis. Initial diagnostic studies with mammography and ultrasound revealed a left-sided hypoechoic mass measuring 2.3 cm, located at the 11 o’clock position adjacent to the nipple-areolar complex. Whole body positron emission tomography–computed tomography scan revealed a hypermetabolic retroareolar left breast mass and enlarged, hypermetabolic left axillary lymph nodes. Final pathology revealed an infiltrating ductal carcinoma with a Nottingham histologic score of 3 (mitotic count score, 3; nuclear pleomorphism score, 3). Of the 19 lymph nodes examined, 15 had evidence of macrometastatic disease. Conclusion: This report highlights a novel case of MBC with a rare genotypic presentation. A need exists to further explore this disease process because the literature is scant with information regarding the long-term treatment and outcomes of MBC, especially in the genotypic form presented here.
  • Understanding Ductal Carcinoma in Situ (DCIS)

    Understanding Ductal Carcinoma in Situ (DCIS)

    Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre Funded by the Australian Government Department of Health and Ageing Understanding ductal carcinoma in situ Contents Acknowledgements .........................................................................................2 How to use this resource ..............................................................................3 Introduction ...........................................................................................................4 Why do I need treatment for DCIS? .........................................................5 Surgery ......................................................................................................................7 Radiotherapy ......................................................................................................11 What is the risk of developing invasive breast cancer or Understanding ductal carcinoma in situ (DCIS) and deciding about treatment was prepared and produced by: DCIS after treatment? ....................................................................................12 National Breast and Ovarian Cancer Centre What follow-up will I need? .......................................................................17 Level 1 Suite 103/355 Crown Street Surry Hills NSW 2010 How can I get more emotional support? .........................................18 Locked Bag 3
  • Male Breast Cancer - Wikipedia, the Free Encyclopedia Pagina 1 Van 5

    Male Breast Cancer - Wikipedia, the Free Encyclopedia Pagina 1 Van 5

    Male breast cancer - Wikipedia, the free encyclopedia pagina 1 van 5 Male breast cancer From Wikipedia, the free encyclopedia Male breast cancer is a relatively rare cancer in Male breast cancer men that originates from Classification and external resources the breast. As it presents a ICD-10 C50 similar pathology as female breast cancer, assessment (http://apps.who.int/classifications/icd10/browse/2010/en#/C50) and treatment relies on ICD-9 175 (http://www.icd9data.com/getICD9Code.ashx? experiences and guidelines icd9=175),175.0 that have been developed (http://www.icd9data.com/getICD9Code.ashx? [1][2][3] in female patients. icd9=175.0),175.9 The optimal treatment is (http://www.icd9data.com/getICD9Code.ashx?icd9=175.9), currently not known. [4] OMIM 114480 (http://omim.org/entry/114480) MedlinePlus 000913 Contents (http://www.nlm.nih.gov/medlineplus/ency/article/000913.htm) eMedicine radio/115 (http://www.emedicine.com/radio/topic115.htm#) ■ 1 Incidence MeSH D001943 (http://www.nlm.nih.gov/cgi/mesh/2013/MB_cgi? ■ 2 Pathology field=uid&term=D001943) ■ 3 Diagnosis ■ 3.1 Staging ■ 4 Differences from female breast cancer ■ 5 Treatment ■ 5.1 Chemotherapeutic and hormonal options in male breast cancer ■ 6 Prognosis ■ 7 References Incidence About one percent of breast cancer develops in males. [4] It is estimated that about 2,140 new cases are diagnosed annually in the US and about 300 in the UK, and the number of annual deaths is about 450 in the US. [2][3] In a study from India, eight out of 1,200 (0.7%) male cancer diagnoses in a pathology review represented breast cancer.
  • Evaluation of the Symptomatic Male Breast

    Evaluation of the Symptomatic Male Breast

    Revised 2018 American College of Radiology ACR Appropriateness Criteria® Evaluation of the Symptomatic Male Breast Variant 1: Male patient of any age with symptoms of gynecomastia and physical examination consistent with gynecomastia or pseudogynecomastia. Initial imaging. Procedure Appropriateness Category Relative Radiation Level Mammography diagnostic Usually Not Appropriate ☢☢ Digital breast tomosynthesis diagnostic Usually Not Appropriate ☢☢ US breast Usually Not Appropriate O MRI breast without and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O Variant 2: Male younger than 25 years of age with indeterminate palpable breast mass. Initial imaging. Procedure Appropriateness Category Relative Radiation Level US breast Usually Appropriate O Mammography diagnostic May Be Appropriate ☢☢ Digital breast tomosynthesis diagnostic May Be Appropriate ☢☢ MRI breast without and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O Variant 3: Male 25 years of age or older with indeterminate palpable breast mass. Initial imaging. Procedure Appropriateness Category Relative Radiation Level Mammography diagnostic Usually Appropriate ☢☢ Digital breast tomosynthesis diagnostic Usually Appropriate ☢☢ US breast May Be Appropriate O MRI breast without and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O Variant 4: Male 25 years of age or older with indeterminate palpable breast mass. Mammography or digital breast tomosynthesis indeterminate or suspicious. Procedure Appropriateness Category Relative Radiation Level US breast Usually Appropriate O MRI breast without and with IV contrast Usually Not Appropriate O MRI breast without IV contrast Usually Not Appropriate O ACR Appropriateness Criteria® 1 Evaluation of the Symptomatic Male Breast Variant 5: Male of any age with physical examination suspicious for breast cancer (suspicious palpable breast mass, axillary adenopathy, nipple discharge, or nipple retraction).
  • Original Article Molecular Subtypes of Male Breast Cancer by Immunohistochemistry

    Original Article Molecular Subtypes of Male Breast Cancer by Immunohistochemistry

    Int J Clin Exp Med 2017;10(1):1670-1677 www.ijcem.com /ISSN:1940-5901/IJCEM0041401 Original Article Molecular subtypes of male breast cancer by immunohistochemistry Huiling Li1*, Yumei Yang2*, Dapeng Wang3, Zhengtian Li4, Dan Zhang5, Fengjuan Xu1 Departments of 1Medical Records and Statistics Room, 4General Surgery, 5Ultrasound, The First Affiliated Hospital of Harbin Medical University, 23 Youzheng Road, Harbin, China; 2Department of Operation Room, The Second Af- filiated Hospital of Harbin Medical University, 246 Xuefu Road, Harbin, China; 3Department of Human Resources, The Third Affiliated Hospital of Harbin Medical University, 150 Haping Road, Harbin, China. *Co-first authors. Received August 11, 2016; Accepted November 20, 2016; Epub January 15, 2017; Published January 30, 2017 Abstract: Male breast cancer is a rare disease, accounting for less than 1% of all breast cancer cases worldwide. Compared to female breast cancer, the incidence of male breast cancer has risen in recent years, and the relation- ship between molecular subtype and clinical behavior has rarely been studied. In this study, we examined the mo- lecular subtypes of male breast cancers based on the expression profile of immunomarkers and their association with clinicopathological features. A total of 98 male breast carcinoma patients were investigated retrospectively using immunostaining for estrogen receptor (ER), progesterone receptor (PR), HER2, Ki-67, and P53. Results were interpreted based on the molecular subtype classification of the 13th St Gallen International Expert Consensus (2013). HER2 expression that was 2+ or 3+ was also evaluated by fluorescent in situ hybridization (FISH) for further validation. The luminal subtype A was the most common in all patients (83.7%, 82/98), followed by the luminal subtype B (16.3%, 16/98).
  • Ductal Carcinoma in Situ

    Ductal Carcinoma in Situ

    Breast Cancer Definition of Ductal Carcinoma In Situ Terms What is Ductal Carcinoma What characterizes DCIS? Ductal: Relating In Situ (DCIS)? DCIS is characterized by pre-can- to the breast’s milk Ductal Carcinoma In Situ is the cerous or early-stage cell abnor- ducts, the parts of the earliest possible and most treat- malities in the breast ducts. On a breast through which able diagnosis of breast cancer. mammogram, DCIS appears as milk fl ows. Some experts consider it to be areas of calcifi cation. “pre-malignant.” The most com- Carcinoma: A type mon form of non-invasive breast How does the pathologist of cancerous, or ma- cancer, DCIS accounts for about make a diagnosis? lignant, tumor. 25 percent of all breast cancers. The pathologist examines biopsy Sometimes, DCIS is seen in as- specimens, In Situ: In its original sociation with an invasive form of along with place. breast cancer. other tests if The diagnosis of DCIS is in- necessary. If Non-invasive: Not spreading beyond the creasing because more women are mammogra- inside of the breast receiving regular mammograms phy shows duct. – and because of advancements in suspicious mammography technology, which fi ndings, a Calcifi cation: Cal- can now fi nd small areas of calci- biopsy may cium deposits in the fi cation in the breast. If untreated, be recom- breast can be associ- about 30 percent of women with mended. A ated with Ductal Car- DCIS will develop invasive breast biopsy is the Ductal Carcinoma cinoma In Situ. Clus- cancer within 10 years of the ini- most widely used method for In Situ is the earliest ters of these deposits tial making a fi rm diagnosis of breast possible and most may indicate cancer.
  • Nipple Adenoma in a Female Patient Presenting with Persistent Erythema

    Nipple Adenoma in a Female Patient Presenting with Persistent Erythema

    Spohn et al. BMC Dermatology (2016) 16:4 DOI 10.1186/s12895-016-0041-6 CASEREPORT Open Access Nipple adenoma in a female patient presenting with persistent erythema of the right nipple skin: case report, review of the literature, clinical implications, and relevancy to health care providers who evaluate and treat patients with dermatologic conditions of the breast skin Gina P. Spohn1*, Shannon C. Trotter1, Gary Tozbikian2 and Stephen P. Povoski3* Abstract Background: Nipple adenoma is a very uncommon, benign proliferative process of lactiferous ducts of the nipple. Clinically, it often presents as a palpable nipple nodule, a visible nipple skin erosive lesion, and/or with discharge from the surface of the nipple skin, and is primarily seen in middle-aged women. Resultantly, nipple adenoma can clinically mimic the presentation of mammary Paget’s disease of the nipple. The purpose of our current case report is to present a comprehensive review of the available data on nipple adenoma, as well as provide useful information to health care providers (including dermatologists, breast health specialists, and other health care providers) who evaluate patients with dermatologic conditions of the breast skin for appropriately clinically recognizing, diagnosing, and treating patients with nipple adenoma. Case presentation: Fifty-three year old Caucasian female presented with a one year history of erythema and induration of the skin of the inferior aspect of the right nipple/areolar region. Skin punch biopsies showed subareolar duct papillomatosis. The patient elected to undergo complete surgical excision with right central breast resection. Final histopathologic evaluation confirmed nipple adenoma. The patient is doing well 31 months after her definitive surgical therapy.
  • 42 Male Breast Cancer C

    42 Male Breast Cancer C

    42 Male Breast Cancer C. Bernard-Marty, E. Azambuja, L. Dal Lago, M.J. Piccart, and F. Cardoso 42.1 Introduction The earliest reference to breast cancer (BC) in men dates from 3000–2500 BCE, on an Egyptian papyrus [11], and the first clinical report was described in the 14th cen- tury by John of Arderne [71]. Carcinoma of the male breast is a relatively rare disease that accounts for less than 1% of all cases of cancer in men. Therefore, BC in men has largely taken a back seat to the worldwide effort to control this disease in women. Similarly, the literature regarding male BC consists mainly of case-control and retrospective studies involv- ing small numbers of patients [28]. The statistical accuracy of the clinical character- istics of male BC is not fully established and knowledge relevant to specific aspects of the disease in men is still limited. Consequently, treatment strategies have been largely guided by extrapolation from experience in women. In this chapter, the available information on risk, prognostic factors, clinical fea- tures, and treatment modalities of male BC has been summarized. Tailored pro- spective clinical trials in this disease, through large Intergroup networks, should be initiated. 42.2 Incidence According to the American Cancer Society, of the 212,600 new cases of BC diag- nosed in 2003, 1,300 (1%) were diagnosed in men and resulted in 400 deaths (30%) [39]. In contrast to the increasing incidence of BC in women, the incidence of BC in men has remained stable over the past 4 decades [47].
  • Breast Cancer in Men: a 10-Year Experience © Permanyer 2019 © Permanyer 2019 of an Oncology Reference Center in Northeast

    Breast Cancer in Men: a 10-Year Experience © Permanyer 2019 © Permanyer 2019 of an Oncology Reference Center in Northeast

    www.journalofcancerology.com PERMANYER J Cancerol. 2019;6:21-7 www.permanyer.com JOURNAL OF CANCEROLOGY HOT TOPIC Breast cancer in men: A 10-year experience © Permanyer 2019 © Permanyer 2019 of an oncology reference center in Northeast . Mexico CARLOS EDUARDO SALAZAR-MEJÍA*, ALAN BURGUETE-TORRES, JUAN FRANCISCO GONZÁLEZ-GUERRERO, DANIEL ALbeRTO GALLEGOS-ARGUIJO, BLANCA OTILIA WImeR-CASTILLO, BRENDA ALEJANDRA SAMANIEGO-SÁENZ, LOURDES PAOLA CHAPA-MONTALVO AND OSCAR VIDAL-GUTIÉRREZ of the publisher Centro Universitario Contra el Cáncer, University Hospital “Dr. José Eleuterio González” and Faculty of Medicine, Universidad Autónoma de Nuevo León, Monterrey, México ABSTRACT Introduction: Breast cancer in men (BCM) accounts for approximately 1% of all breast cancer cases. The present study aimed at describing the clinical and demographic characteristics of BCM in Mexican population. Methods: We performed a retrospective analysis of the men with newly diagnosed breast cancer treated in an oncology referral center in Northeast Mexico from 2007 to 2017. Results: Fifteen patients were included in the analysis. Mean age at diagnosis was 60.7 years and median time from diagnosis to the start of treatment was 2 months. About 73% of patients presented with locoregional disease (clinical stage [CS] I-III) and 26.7% were classified as Stage IV disease on their first assessment. All patients had invasive ductal carcinoma and 60.0% were Grade II tumors. Twelve cases were positive for hormone receptors and none showed overexpression of human epidermal growth factor receptor 2. Regarding primary treatment, 12 patients underwent a modified radical mastectomy and two underwent breast-conserving surgery. The majority of patients received chemotherapy and radiotherapy in the adjuvant setting and tamoxifen was the drug of choice in all patients considered as candidates for hor- monal therapy.
  • Of Male Breast Cancer

    Of Male Breast Cancer

    2.6 HOURS Continuing Education ORIGINAL RESEARCH By Eileen Thomas, PhD, RN Men’s Awareness and Knowledge of Male Breast Cancer A STUDY OF MEN A T HIGHER RISK PROVIDES A N EVIDENCE -B A SED UNDER - ST A NDING OF MEN ’S PERCEPTIONS OF THIS DISE A SE . reast cancer in men is uncommon, account - ABSTRACT ing for less than 1% of all breast cancers This article reports on the findings of a qualitative Objective: and less than 1% of all carcinomas in men.1 study that explored the awareness and knowledge of male breast In­­cidence trends are less clear. One large U.S. cancer among English-speaking men. The primary goal was to elicit population–based study by Giordano and information to guide both clinical practice and the development of Bcolleagues revealed that, between 1973 and 1998, the gender-specific educational interventions. incidence of male breast cancer increased by 26%, Methods: Interviews with 28 adult men, all of whom had no while that of female breast cancer rose by 52%.1 More history of breast cancer themselves but had at least one maternal recently, the American Cancer Society (ACS) has re - blood relative with the disease, were conducted and analyzed, using ported that although the rate of female breast cancer qualitative methods, to describe participants’ awareness of male has been declining,2 “the number of breast cancer cases breast cancer, their knowledge of the disease, and how they thought in men relative to the population has been fairly stable awareness of male breast cancer could be increased in health care over the last 30 years.”3 The ACS also estimates that, providers and the lay public.
  • Incidental Detection of Carcinoma in Situ in Fibroadenoma of Breast in a Young Woman: a Rare Finding

    Incidental Detection of Carcinoma in Situ in Fibroadenoma of Breast in a Young Woman: a Rare Finding

    Online - 2455-3891 Vol 12, Issue 1, 2019 Print - 0974-2441 Case Report INCIDENTAL DETECTION OF CARCINOMA IN SITU IN FIBROADENOMA OF BREAST IN A YOUNG WOMAN: A RARE FINDING NIKITHA VALERINA KAIRANNA1*, BRIJMOHAN KUMAR SINGH2, PAVITHRA P1 1Department of Pathology, Melaka Manipal Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India. 2 Department of Pathology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, India. Email: [email protected] Received 07 July 2018, Revised and Accepted: 17 August 2018 ABSTRACT Fibroadenoma is the most common benign tumor of the breast in young females. Breast cancer arising within a fibroadenoma is a rare phenomenon. The incidence of carcinoma within a fibroadenoma is reported to be between 0.1% and 0.3% in a screened population, with a peak age of occurrence between the 4th and 5th decade. We present a case of 29-year-old female with ductal carcinoma in situ in a background of fibroadenoma. There is a low percentage of fibroadenomas harboring carcinoma; however, all breast lumps should be seriously managed; extirpation and histological examination is recommended. Keywords: Fibroadenoma, Carcinoma in situ, Benign tumor. © 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i1.28326 INTRODUCTION Ultrasound of both the breasts revealed well-circumscribed, homogenous, and hypoechoic lesions. The features were suggestive of Fibroadenoma is the most common benign tumor of the breast in fibroadenoma of bilateral breasts (Fig.